Gerraldine Harriman
Fondateur chez HotSpot Therapeutics, Inc.
Profil
Gerraldine Harriman is the founder of HotSpot Therapeutics, Inc. founded in 2017, where she holds the title of Chief Scientific Officer.
Currently, she is an Advisor at Atlas Venture Advisors, Inc. since 2016.
Previously, she held the position of Vice President & Head of Chemistry at Galenea Corp.
from 2007 to 2010 and Vice President at Nimbus Therapeutics LLC from 2010 to 2016.
Dr. Harriman received a doctorate degree from the University of Rhode Island in 1991 and an undergraduate degree from American International College in 1986.
Postes actifs de Gerraldine Harriman
| Sociétés | Poste | Début |
|---|---|---|
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | 01/01/2016 |
HotSpot Therapeutics, Inc.
 HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Fondateur | 01/01/2017 |
Anciens postes connus de Gerraldine Harriman
| Sociétés | Poste | Fin |
|---|---|---|
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Private Equity Investor | 31/10/2016 |
Galenea Corp.
 Galenea Corp. Pharmaceuticals: MajorHealth Technology Galenea Corp. is an emerging biotechnology company which engaged in the discovery of novel therapies for central nervous system (CNC) and respiratory diseases. The firm is focusing initially on utilizing proprietary technologies to generate calcineurin-related treatments for schizophrenia. It also offers synaptic transmission drug discovery platform for alzheimer’s disease (AD), parkinson’s disease, huntington’s disease, epilepsy, bipolar depression, schizophrenia, autism spectrum disorders, and traumatic brain injury. The company was founded Jianzhu chen, Susumu Tonegawa, Maria Karayiorgou, and David J. Gerber in 2004 and is headquartered in Wakefield, MA. | Private Equity Investor | 30/11/2010 |
Formation de Gerraldine Harriman
| University of Rhode Island | Doctorate Degree |
| American International College | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Health Technology |
Nimbus Therapeutics LLC
Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Health Technology |
Galenea Corp.
Galenea Corp. Pharmaceuticals: MajorHealth Technology Galenea Corp. is an emerging biotechnology company which engaged in the discovery of novel therapies for central nervous system (CNC) and respiratory diseases. The firm is focusing initially on utilizing proprietary technologies to generate calcineurin-related treatments for schizophrenia. It also offers synaptic transmission drug discovery platform for alzheimer’s disease (AD), parkinson’s disease, huntington’s disease, epilepsy, bipolar depression, schizophrenia, autism spectrum disorders, and traumatic brain injury. The company was founded Jianzhu chen, Susumu Tonegawa, Maria Karayiorgou, and David J. Gerber in 2004 and is headquartered in Wakefield, MA. | Health Technology |
